Cargando…

High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome

PURPOSE: To report the relapse and survival rates associated to treatment for patients with stage IC, grade 2 or grade 3 and IB grade 3 diseases considered high risk patients group for relapse. MATERIALS AND METHODS: From January 1993 to December 2003, 106 patients with endometrial cancer stage I we...

Descripción completa

Detalles Bibliográficos
Autores principales: Viani, Gustavo A, Patia, Barbara F, Pellizzon, Antonio C, De Melo, Marcel D, Novaes, Paulo E, Fogaroli, Ricardo C, Conte, Maria A, Salvajoli, Joao V
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1555589/
https://www.ncbi.nlm.nih.gov/pubmed/16887018
http://dx.doi.org/10.1186/1748-717X-1-24
_version_ 1782129360258465792
author Viani, Gustavo A
Patia, Barbara F
Pellizzon, Antonio C
De Melo, Marcel D
Novaes, Paulo E
Fogaroli, Ricardo C
Conte, Maria A
Salvajoli, Joao V
author_facet Viani, Gustavo A
Patia, Barbara F
Pellizzon, Antonio C
De Melo, Marcel D
Novaes, Paulo E
Fogaroli, Ricardo C
Conte, Maria A
Salvajoli, Joao V
author_sort Viani, Gustavo A
collection PubMed
description PURPOSE: To report the relapse and survival rates associated to treatment for patients with stage IC, grade 2 or grade 3 and IB grade 3 diseases considered high risk patients group for relapse. MATERIALS AND METHODS: From January 1993 to December 2003, 106 patients with endometrial cancer stage I were managed surgically in our institution. Based on data from the medical records, 106 patients with epithelial endometrial cancer met the following inclusion criteria: stage IC grade 2 or 3 and IB grade 3 with or without lymphovascular invasion. Staging was defined according to the FIGO surgical staging system. Postoperative adjuvant radiotherapy consisted of external beam pelvic radiation, vaginal brachytherapy alone or both. The median age was 65 years (range, 32–83 years), lymph node dissection was performed in 45 patients (42.5%) and 14 patients (13.2%) received vaginal brachytherapy only, and 92 (86.8%) received combined vaginal brachytherapy and external beam radiotherapy. The median dose of external beam radiotherapy administered to the pelvis was 4500 cGy (range 4000 – 5040). The median dose to vaginal surface was 2400 cGy (range 2000 – 3000). Predominant pathological stage and histological grade were IC (73.6%) and grade 3 (51.9%). The lymphovascular invasion was present in 33 patients (31.1%) and pathological stage IC grade 2 was most common (48. 1%) combination of risk factors in this group. RESULTS: With a follow up median of 58.3 months (range 12.8 – 154), five year overall survival and event free survival were 78.5% and 72.4%, respectively. Locoregional control in five year was 92.4%. Prognostic factors related with survival in univariate analyses were: lymphadenectomy (p = 0.045), lymphovascular invasion (p = 0.047) and initial failure site (p < 0.0001). In multivariate analyses the initial failure in distant sites (p < 0.0001) was the only factor associated with poor survival. Acute and chronic gastrointestinal and genitourinary toxicity grades 3 were not observed. CONCLUSION: In conclusion, our results showed that the stage IC, grade 2, 3 and IB grade 3 endometrial cancer was associated with significantly increased risk of distant relapse and endometrial carcinoma-related death independently of salvage treatment modality.
format Text
id pubmed-1555589
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15555892006-08-26 High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome Viani, Gustavo A Patia, Barbara F Pellizzon, Antonio C De Melo, Marcel D Novaes, Paulo E Fogaroli, Ricardo C Conte, Maria A Salvajoli, Joao V Radiat Oncol Research PURPOSE: To report the relapse and survival rates associated to treatment for patients with stage IC, grade 2 or grade 3 and IB grade 3 diseases considered high risk patients group for relapse. MATERIALS AND METHODS: From January 1993 to December 2003, 106 patients with endometrial cancer stage I were managed surgically in our institution. Based on data from the medical records, 106 patients with epithelial endometrial cancer met the following inclusion criteria: stage IC grade 2 or 3 and IB grade 3 with or without lymphovascular invasion. Staging was defined according to the FIGO surgical staging system. Postoperative adjuvant radiotherapy consisted of external beam pelvic radiation, vaginal brachytherapy alone or both. The median age was 65 years (range, 32–83 years), lymph node dissection was performed in 45 patients (42.5%) and 14 patients (13.2%) received vaginal brachytherapy only, and 92 (86.8%) received combined vaginal brachytherapy and external beam radiotherapy. The median dose of external beam radiotherapy administered to the pelvis was 4500 cGy (range 4000 – 5040). The median dose to vaginal surface was 2400 cGy (range 2000 – 3000). Predominant pathological stage and histological grade were IC (73.6%) and grade 3 (51.9%). The lymphovascular invasion was present in 33 patients (31.1%) and pathological stage IC grade 2 was most common (48. 1%) combination of risk factors in this group. RESULTS: With a follow up median of 58.3 months (range 12.8 – 154), five year overall survival and event free survival were 78.5% and 72.4%, respectively. Locoregional control in five year was 92.4%. Prognostic factors related with survival in univariate analyses were: lymphadenectomy (p = 0.045), lymphovascular invasion (p = 0.047) and initial failure site (p < 0.0001). In multivariate analyses the initial failure in distant sites (p < 0.0001) was the only factor associated with poor survival. Acute and chronic gastrointestinal and genitourinary toxicity grades 3 were not observed. CONCLUSION: In conclusion, our results showed that the stage IC, grade 2, 3 and IB grade 3 endometrial cancer was associated with significantly increased risk of distant relapse and endometrial carcinoma-related death independently of salvage treatment modality. BioMed Central 2006-08-03 /pmc/articles/PMC1555589/ /pubmed/16887018 http://dx.doi.org/10.1186/1748-717X-1-24 Text en Copyright © 2006 Viani et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Viani, Gustavo A
Patia, Barbara F
Pellizzon, Antonio C
De Melo, Marcel D
Novaes, Paulo E
Fogaroli, Ricardo C
Conte, Maria A
Salvajoli, Joao V
High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title_full High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title_fullStr High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title_full_unstemmed High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title_short High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
title_sort high-risk surgical stage 1 endometrial cancer: analysis of treatment outcome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1555589/
https://www.ncbi.nlm.nih.gov/pubmed/16887018
http://dx.doi.org/10.1186/1748-717X-1-24
work_keys_str_mv AT vianigustavoa highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT patiabarbaraf highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT pellizzonantonioc highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT demelomarceld highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT novaespauloe highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT fogaroliricardoc highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT contemariaa highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome
AT salvajolijoaov highrisksurgicalstage1endometrialcanceranalysisoftreatmentoutcome